Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00209443
Other study ID # SOV302
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 2004
Est. completion date February 28, 2006

Study information

Verified date April 2019
Source GE Healthcare
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Magnetic Resonance Angiography (MRA) is an examination similar to Magnetic Resonance Imaging (MRI) which uses a magnetic field and a contrast medium when needed to visualize blood flow in the arterial vessels throughout the body.

Gadodiamide, a contrast medium, is already approved and is used to image blood vessels by directly injecting it into the vein, but this procedure has not been formally tested to image the aorto-iliac vessels using MR.

The study is designed to determine the presence or absence of a relevant stenosis (ie greater than/equal to 50%) or occlusion in aorto-iliac arteries. Intra-arterial Digital Subtraction Angiography (IADSA) will be used as the standard of truth.


Description:

GEHC has decided not to provide this detail


Recruitment information / eligibility

Status Completed
Enrollment 407
Est. completion date February 28, 2006
Est. primary completion date February 28, 2006
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Study subjects must be adults with confirmed or suspected aorto-iliac stenosis.

- The subject must have been referred for Digital Subtraction Angiography.

Exclusion Criteria:

- The subject has a known hypersensitivity to either conventional X-ray or gadolinium based MR contrast media including, but not restricted to, the investigational product.

- The subject is lactating.

- The subject is pregnant as defined by a serum or urine beta-HCG pregnancy test obtained within 24 hours before administration of the investigational product.

- The subject received or is scheduled to receive MRI contrast medium within 24 hours prior to or less than 24 hours after administration of the investigational product.

- The subject received or is scheduled to receive X-ray contrast medium within 24 hours prior to or less than 24 hours after administration of the investigational product.

- The subject received an investigational product other than OMNISCAN (gadodiamide) within 30 days prior to OMNISCAN administration or will receive an investigational product within the follow-up period proposed for this study.

- The subject presents any clinically active, serious, life-threatening disease with a life expectancy of less than 6 months.

- The subject has a serum creatinine value of >= 3.5 mg/dL (309.4 µmol/L).

- The subject has previously been included in this study.

- The subject has a contra-indication for MRI according to accepted clinical guidelines.

- The subject has metal implants and/or stents in the aorto-iliac region and/or hip replacement.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Gadodiamide Injection


Locations

Country Name City State
Germany Amersham Buchler GmbH & Co. KG Ismaning

Sponsors (1)

Lead Sponsor Collaborator
GE Healthcare

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Differences in subject level and vessel level sensitivity and specificity between CE-MRA and TOF-MRA in detecting stenosis,(>50% occlusion) in aorto-iliac arteries. IA-DSA is the truth standard. 27 hours
Secondary Differences in sensitivity, specificity, accuracy, PPV and NPV at subject and/or vessel level between CE-MRA and TOF-MRA in detecting stenosis (50% occlusion) in aorta-iliac arteries; Revascularisation strategies based on CE-MRA, TOF-MRA and IA DSA 27 hours
See also
  Status Clinical Trial Phase
Completed NCT03724279 - Crossing Atheroma or Thrombus With ByCross Device for Revascularization of Peripheral Arteries of Diameter ≥ 3mm N/A
Recruiting NCT04390672 - Multivessel TALENT N/A
Not yet recruiting NCT02841488 - Ischemic Pain Control With Analgesic Methods Clinical Trial Phase 3
Completed NCT00371371 - Intra-arterial Stem Cell Therapy for Patients With Chronic Limb Ischemia (CLI) Phase 1/Phase 2
Completed NCT00174759 - CASPAR : Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease Phase 3
Completed NCT00000539 - Arterial Disease Multifactorial Intervention Trial (ADMIT) Phase 3
Recruiting NCT04089943 - The Role of microRNA-210 in Regulating Oxidative Stress in Patients With PAD N/A
Recruiting NCT04343209 - Ammonia N-13 Myocardial Blood Flow Absolute Quantification by PET in Patients With Known or Suspected CAD (Ammonia MAP)
Not yet recruiting NCT05930145 - Results of the Use of Two Stentrievers Simultaneosly Compared With One as a Primary Treatment in Acute Ischemic Stroke N/A
Recruiting NCT04142021 - Safety and Feasibility Evaluation of Planning and Execution of Surgical Revascularization Solely Based on Coronary CTA and FFRCT in Patients With Complex Coronary Artery Disease (FASTTRACK CABG)
Completed NCT03253692 - Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Active, not recruiting NCT04624854 - Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) Phase 4
Active, not recruiting NCT02921230 - Trial Comparing ELUVIA Versus Bare Metal Stent in Treatment of Superficial Femoral and/or Proximal Popliteal Artery N/A
Recruiting NCT02593994 - IRIS-Onyx Cohort in the IRIS-DES Registry
Completed NCT02008097 - Clinical Benefits of B-Flow Ultrasound N/A
Terminated NCT01462721 - The eSVS® Mesh Randomized Post-Market Study N/A
Completed NCT00282646 - Safety and Feasibility Study of Autologous Bone Marrow Cell Transplantation in Patients With Peripheral Arterial Occlusive Disease (PAOD) Phase 2
Not yet recruiting NCT04956523 - Preliminary Tissue Monitoring During Endovascular Intervention Study
Recruiting NCT05616104 - FLEX FIRST Registry Research Protocol
Not yet recruiting NCT04175197 - LegDeb2 Global Registry for Use of Legflow in Peripheral Arteries